Could an Impairment in Local Translation of mRNAs in Glia be Contributing to Pathogenesis in ALS? by Barton, Samantha K. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Could an Impairment in Local Translation of mRNAs in Glia be
Contributing to Pathogenesis in ALS?
Citation for published version:
Barton, SK, Gregory, JM, Chandran, S & Turner, BJ 2019, 'Could an Impairment in Local Translation of
mRNAs in Glia be Contributing to Pathogenesis in ALS?' Frontiers in Molecular Neuroscience, vol. 12. DOI:
10.3389/fnmol.2019.00124
Digital Object Identifier (DOI):
10.3389/fnmol.2019.00124
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Frontiers in Molecular Neuroscience
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 08. Jul. 2019
MINI REVIEW
published: 21 May 2019
doi: 10.3389/fnmol.2019.00124
Edited by:
Jochen C. Meier,
Technische Universitat
Braunschweig, Germany
Reviewed by:
Jean-Marc Gallo,
King’s College London,
United Kingdom
David W. Walker,
RMIT University, Australia
*Correspondence:
Samantha K. Barton
samantha.barton@florey.edu.au
†These authors have contributed
equally to this work
Received: 18 February 2019
Accepted: 26 April 2019
Published: 21 May 2019
Citation:
Barton SK, Gregory JM, Chandran S
and Turner BJ (2019) Could an
Impairment in Local Translation of
mRNAs in Glia be Contributing to
Pathogenesis in ALS?
Front. Mol. Neurosci. 12:124.
doi: 10.3389/fnmol.2019.00124
Could an Impairment in Local
Translation of mRNAs in Glia be
Contributing to Pathogenesis in ALS?
Samantha K. Barton1,2,3*, Jenna M. Gregory2,3,4, Siddharthan Chandran2,3,4†
and Bradley J. Turner1†
1Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia, 2Euan MacDonald
Centre for MND Research, University of Edinburgh, Edinburgh, United Kingdom, 3Centre for Clinical Brain Sciences,
University of Edinburgh, Edinburgh, United Kingdom, 4UK Dementia Research Institute at University of Edinburgh, Edinburgh,
United Kingdom
One of the key pathways implicated in amyotrophic lateral sclerosis (ALS) pathogenesis
is abnormal RNA processing. Studies to date have focussed on defects in RNA
stability, splicing, and translation, but this review article will focus on the largely
overlooked RNA processing mechanism of RNA trafficking, with particular emphasis
on the importance of glia. In the central nervous system (CNS), oligodendrocytes can
extend processes to myelinate and metabolically support up to 50 axons and astrocytes
can extend processes to cover up to 100,000 synapses, all with differing local functional
requirements. Furthermore, many of the proteins required in these processes are large,
aggregation-prone proteins which would be difficult to transport in their fully translated,
terminally-folded state. This, therefore, highlights a critical requirement in these cells
for local control of protein translation, which is achieved through specific trafficking
of mRNAs to each process and local translation therein. Given that a large number
of RNA-binding proteins have been implicated in ALS, and RNA-binding proteins are
essential for trafficking mRNAs from the nucleus to glial processes for local translation,
RNA misprocessing in glial cells is a likely source of cellular dysfunction in ALS. To date,
neurons have been the focus of ALS research, but an intrinsic deficit in glia, namely
astrocytes and oligodendrocytes, could have an additive effect on declining neuronal
function in ALS. This review article aims to highlight the key evidence that supports
the contention that RNA trafficking deficits in astrocytes and oligodendrocytes may
contribute to in ALS.
Keywords: RNA trafficking, local translation, ALS, oligodendrocytes, astrocytes
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are characterized
pathologically by the accumulation of cytoplasmic inclusions in affected neurons and glial cells
that, in 97%–98% of cases, stain positive for TAR-DNA binding protein 43 (TDP-43; Neumann
et al., 2006). TDP-43, like many of the proteins that have been associated with ALS pathogenesis, is
a DNA and RNA-binding protein, implicating impaired RNA processing as a possible mechanism
of disease.
Regulatory proteins bind to mRNA transcripts to aid in localization, translation and stability,
whilst also playing important roles in transcription, alternative splicing and nuclear export.
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The binding of regulatory proteins to mRNAs, as well as the
accrual of various translation factors, forms an RNA granule.
Dysregulation of RNA granule formation has been implicated
in neurodegenerative disease (Buchan, 2014), including ALS
and FTD (Fan and Leung, 2016). Their involvement ranges
from an impaired ability of the RNA granule to sufficiently aid
in localization, translation and stability of the mRNAs, to the
formation of stress granules, all of which have been implicated in
ALS and can initiate a cascade of downstream events predicted
to play a role in neuronal decline (Fan and Leung, 2016).
This review article will focus specifically on impaired mRNA
localization, which is due to compromised nucleocytoplasmic
export and impaired trafficking to glial processes.
Subcellular transportation of mRNAs provides cells with the
ability to translate proteins in response to localized signals. Local
translation has been extensively documented in neuronal cell
types and is noted to be essential for their normal function
as it allows a high level of cellular autonomy from the cell
soma to the dendrites, particularly during axonal pathfinding
(Yoon et al., 2009). It is also established that glia within
the central nervous system (CNS) undergo local translation.
The cellular complexity of glia coupled with their elaborate
roles in the CNS (ranging from input into vascular control to
providing physical, trophic and metabolic support to neurons
to the stabilization of synapses) renders the requirement for
local translation essential to allow the translation of proteins
unique to the specific function of each glial process. Further,
the dynamic nature of processes like myelination and synaptic
activity means that cells can respond more readily. These
concepts have not been extensively explored in disease models.
The aggregation of RNA-binding proteins, and associated
proteins involved in RNA trafficking, in pathological inclusions
in ALS is well established and so this review article aims
to detail what impact these aggregations could have on
local translation of key mRNAs in glia. We propose that
the proteinopathy present in the majority of ALS patients
could be impacting on local translation of mRNAs, thereby
hindering the normal function of glia in patients with ALS
and FTD, potentially contributing to neuronal decline and
disease progression.
GLIAL INVOLVEMENT IN ALS
Humans have the highest proportion of glial cells, with their
primary role being to support neuronal function, whether that be
via structural support, metabolic and trophic support or through
protection from surrounding threats to neuronal health. Broadly,
glial cells encompass oligodendrocytes, astrocytes and specialized
immune cells called microglia. For the purpose of this review
article, we will focus on non-immune glial cells; their key roles
(all of which depend on effective mRNA trafficking and local
translation) are highlighted in Figure 1.
Given the importance of glia as neuronal support
cells, intrinsic glial dysfunction has been implicated in
neurodegenerative diseases including ALS (Yamanaka et al.,
2008; Kang et al., 2013; Serio et al., 2013; Ferraiuolo et al.,
2016; Madill et al., 2017). In the TDP-43Q331K mouse model, it
was shown that selective removal of the mutation from motor
neurons alone did not prevent motor neuron or neuromuscular
junction loss and did not reduce the activation of microglia
or astrocytes (Ditsworth et al., 2017). More specifically, it has
been shown that co-culturing induced pluripotent stem cell
(iPSC)-derived oligodendrocytes from sporadic ALS patients, as
well as those harboring mutations in C9orf72 and TDP-43, with
HB9-GFP motor neurons led to significant motor neuron loss
compared to co-cultures with iPSC-derived oligodendrocytes
from healthy control patients (Ferraiuolo et al., 2016). Similarly,
a detrimental effect of co-cultured astrocytes (derived from
neural precursor cells isolated from post-mortem tissue of
sporadic ALS patients) on mouse embryonic stem cell-derived
motor neurons survival was also observed (Haidet-Phillips et al.,
2011). Thus, glia are critically involved in ALS pathogenesis.
The majority of research into glial influence in ALS and
FTD to date has been on what impact glial dysfunction has
on neuronal health. This is obviously relevant given that the
symptoms experienced by ALS patients are related to the loss
of upper and lower motor neurons. However, it is important
to also address the intrinsic glial deficit. What tends to be
underappreciated is that glia have the metabolically demanding
role of not only sustaining their own functions but are also
required to support the surrounding environment. Astrocytes
and oligodendrocytes, in particular, are required to metabolically
support neuronal function by directly shuttling lactate to neurons
as their primary fuel source (Dienel and Cruz, 2004; Fünfschilling
et al., 2012; Saab et al., 2013, 2016). Thus, any process that
amplifies metabolic demand, or interferes with normal metabolic
processes, would have a detrimental effect directly on cellular
function and indirectly on surrounding neurons. So, we suggest
that impaired RNA processing in glia could be contributing to
ALS and FTD pathogenesis.
ALS-LINKED RNA-BINDING PROTEINS
Many known genetic mutations linked with ALS and FTD are
in genes involved in maintaining RNA homeostasis. Examples
includeTARDBP (encoding TDP-43), FUS RNA-binding protein
(FUS), C9orf72 and, to a lesser extent, heterogeneous nuclear
ribonucleoproteins A1 (hnRNP A1) and A2/B1 (hnRNP A2/B1),
EWS RNA-binding protein 1 (EWSR1), angiogenin (ANG),
senataxin (SETX), matrin 3 (MATR3) ataxin-2 (ATXN2) and
TATA-box binding protein associated factor 15 (TAF15; Ling
et al., 2013; Kapeli et al., 2017). Many of these proteins have
both loss-of-function and gain-of-function toxic effects on
cells. For example, iPSC-derived motor neurons from patients
harboring a mutation in the hnRNP A2/B1 gene not only lost
the function of this protein but also gained toxicity linked to
failure in RNA processing (Martinez et al., 2016). The hypothesis
that RNA-binding proteins aggregating in the cytoplasm of
neurons being a pathogenic mechanism in ALS is not a new
concept and has been suggested, and reviewed (Yasuda and Mili,
2016), previously. Briefly, it is suggested that the aggregation
of RNA-binding proteins limits RNA transport along neuronal
microtubules thus preventing local translation at the dendrites
and even leading to ectopic translation in the cell body. RNA
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FIGURE 1 | The key roles of oligodendrocytes and astrocytes in the brain that rely on local translation of mRNAs. Astrocytes and oligodendrocytes have the
ultimate role of supporting neuronal function. Astrocytes have a plethora of functions that range from structurally supporting synapse formation (1) to providing
general structural support in the central nervous system (CNS) (2), especially in development during axon formation and pathfinding. Oligodendrocytes have the
metabolically demanding function of myelinating axons for accelerated conductance (3) and it is through these myelin sheaths that oligodendrocytes can shuttle
metabolic and trophic factors to neurons (3). Astrocytes are also critical in providing metabolic and trophic support to neurons (4) and can also shuttle metabolites to
oligodendrocytes for their own use or to shuttle onwards to neurons (5). Astrocytes are also important for blood vessel stability and assist in tight junction formation;
they also can receive glucose from the bloodstream (6) and can shuttle this to oligodendrocytes or themselves convert it to lactate (the end-product of glycolysis of
glucose and the energy substrate for neurons) and shuttle this to oligodendrocytes as well or directly to neurons. Importantly, the key sites of support to neurons
occur at the distal processes, thus local translation of mRNAs is critically important to ensure these processes are dynamic and in rapid response to the surrounding
environment’s requirements.
trafficking in glia in ALS remains relatively unexplored but we
predict similar processes could apply and contribute to cellular
pathogenesis. The current understanding of these processes is
detailed below.
Many of the ALS-associated pathogenic proteins are known
to be essential for nucleo-cytoplasmic mRNA trafficking and,
importantly, many will interact with one another for efficient
RNA metabolism. These interactions are highlighted in Figure 2;
they have been reviewed elsewhere (Dormann and Haass, 2013;
Vanderweyde et al., 2013; Balendra and Isaacs, 2018) so we will
detail only those of relevance to glial mRNA trafficking.
TDP-43 has multiple roles in RNA processing and is
known to bind to more than 6,000 RNA targets, equating to
approximately 30% of the human transcriptome (Ling et al.,
2013); it is topologically and functionally dysregulated in 97%
of ALS patients (Neumann et al., 2006, 2007; Seilhean et al.,
2009; Murray et al., 2011; Armstrong, 2017). FUS binds to
over 5,000 RNA targets in the brain (Ling et al., 2013) but
is topologically and functionally dysregulated in <1% of ALS
patients and 9% of FTD patients (Blokhuis et al., 2013; Ling
et al., 2013). Both TDP-43 and FUS have been associated with
hnRNP A1 (Kamelgarn et al., 2016) with TDP-43 specifically
linked with aberrant splicing of hnRNP A1 (Deshaies et al., 2018)
and altered expression and aberrant splicing of hnRNP A2/B1
(Highley et al., 2014). Coady and Manley (2015) used the human
glioblastoma cell line, U87, to show that mutations in FUS can
lead to reduced MeCP2 levels (a transcription factor regulator);
reduced MeCP2 protein levels in glia has previously been shown
to be toxic to neurons leading to altered dendritic morphology
and, ultimately, neuronal death (Ballas et al., 2009).
The most common genetic mutation underlying ALS and
FTD is the C9orf72 hexanucleotide repeat expansion (HRE),
which pathologically presents as G4C2 repeat RNA foci and sense
and anti-sense repeat-associated non-ATG (RAN) translation of
di-peptide repeat proteins (DPRs) as well as TDP-43 aggregation.
G4C2 repeat RNA foci co-localize with various RNA-binding
proteins in neurons, including hnRNP A1 and hnRNP H/F,
shown in post-mortem tissue (Cooper-Knock et al., 2014) and
in cell lines, primary neurons and zebrafish embryos (Lee et al.,
2013; Conlon et al., 2016). Of relevance, this has also been
validated in human astrocytes derived from the autopsied motor
cortex (Conlon et al., 2016). In addition to being an RNA-binding
protein, hnRNP H is a key splicing regulator; notably, hnRNP
H splices transcripts encoding other splicing proteins, which
includes TDP-43 and FUS (Uren et al., 2016). Other RNA
and nucleic acid-binding proteins known to bind to the G4C2
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FIGURE 2 | Protein binding partners that have been implicated in ALS. 97–98% of ALS patients have pathogenic protein inclusions that stain positive for the
RNA/DNA binding protein TDP-43. Most of the remaining 2%–3% of patients will have inclusions that stain positive for FUS. Currently, the most prevalent genetic
mutation associated with familial and sporadic ALS is the C9orf72 hexanucleotide repeat expansion (HRE); these patients characteristically have TDP-43-positive
inclusions and/or TDP-43-negative, ubiquitin-positive inclusions and/or pathogenic RNA foci (composed of GGGGCC repeats), all of which are known to sequester
RNAs and proteins. Many of the RNA-binding proteins in this schematic are critical for RNA trafficking and local translation of key mRNAs in astrocytes and
oligodendrocytes.
repeats are hnRNP A3, which is important for nuclear export of
mRNAs (Mori et al., 2013). DPRs have been more challenging
to characterize given the limited access to efficient antibodies.
In vitro work has demonstrated that DPRs are highly prone to
aggregation and can sequester proteins, including RNA-binding
proteins, which could contribute to abnormal RNA trafficking in
neurons and glia (Gendron et al., 2013; Porta et al., 2015). DPRs
can dock at the nuclear pore and disrupt the architecture of the
nuclear envelope leading to limited nuclear import and export of
macromolecules and mRNAs (Jovicˇic´ et al., 2015; Zhang et al.,
2016; Shi et al., 2017). Both poly(GR) and poly(PR), two of the
five DPRs, have been shown to interact with TDP-43-positive
RNA as well as stress granules and are predicted to be involved
in the fibrillization of TDP-43 and other RNA-binding proteins
such as hnRNP A2/B1 (Molliex et al., 2015; Freibaum and Taylor,
2017). Importantly, Edbauer and colleagues demonstrated that
poly(GA) can cause mislocalization of TDP-43 in neurons
(Khosravi et al., 2017).
RNA TRAFFICKING IN ASTROCYTES
Astrocytes are the most abundant cell type in the human
brain, with functions including: (i) neuronal support, including
metabolic, trophic and structural support; (ii) neuronal synapse
and axon formation; and (iii) regulation of cerebral blood flow
(Blackburn et al., 2009). Their role in neurodegeneration remains
contentious with astrocytes believed to have both protective
and harmful effects (Phatnani and Maniatis, 2015), much like
microglia (Geloso et al., 2017). Astrocytes have a complex
morphology; in cerebral gray matter their processes can span
50 µm and up to 300 µm in the white matter, rendering
local translation necessary for normal cellular function. There
is also a high metabolic demand on astrocytes, both for their
own function as well as metabolically supporting neurons;
one astrocyte can be responsible for being in contact with
up to 100,000 synapses (Sakers et al., 2017) covering a
surface area of between 60,000 and 80,000 µm2. The dynamic
nature of astrocytic function means these cells have optimized
their protein availability relying heavily on local translation
(Boulay et al., 2017).
Glial fibrillary acidic protein (GFAP) mRNA is known
to be translated locally at astrocytic processes and is an
abundantly expressed protein in all astrocytes, despite the
known heterogeneity among the astrocyte population. To further
validate this, it has been shown to equate to 15% of an astrocyte’s
volume and the protein expression is isolated predominantly
to its processes (Bushong et al., 2002). GFAP-null mice ranged
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in phenotype, but half of the cohort were seen to have
extensive deficits including abnormal myelination, reduced white
matter vascularization and decreased integrity of the blood
brain barrier (Liedtke et al., 1996). The RNA-binding protein
responsible for shuttling GFAP to the peripheral astrocyte
processes (PAP) is Quaking (QKI; Sakers et al., 2017). QKI
is abundantly expressed in oligodendrocytes and astrocytes
and has been implicated in schizophrenia (Aberg et al., 2006)
and brain cancers (Molenaar et al., 2012) but is yet to be
associated with ALS pathology. However, given it is known
to bind to 2,500 mRNAs, as well as its close relationship to
other affected RNA-binding proteins (it contains a hnRNP
K homology domain, an hnRNP that has been implicated in
ALS; Hafner et al., 2010), it deserves further investigation.
Another key astrocytic mRNA known to be locally translated
is excitatory amino acid transporter-2 (EAAT2) and whilst
its trafficking has not been explored, EAAT2 transcripts with
both intron-retention and exon-skipping have been found in
65% of sporadic ALS patients in neuropathologically affected
areas as well as in the cerebrospinal fluid (CSF; Lin et al.,
1998). Other mRNAs known to be translated locally include
Aqp4 (encoding the main water channel protein in the
CNS responsible for maintaining water homeostasis), Aldh1a1
(encoding an enzyme that depicts mature astrocytes; Boulay
et al., 2017), Slc1a2, Slc1a3 and GluI (encoding enzymes
important for glutamate metabolism), Fads1, Fads2, Scd1,
Scd2, Elovl5 and Hadha (encoding enzymes critical for fatty
acid synthesis), Kif1c and Myo1D (encoding proteins that
maintain the cytoskeleton), Mertk, Sparc and Thbs4 (encoding
proteins key for synapse regulation), ApoE (encoding a class of
proteins required for fat metabolism) and CLU (encoding the
chaperone protein clusterin that has been implicated in ALS;
Sakers et al., 2017).
Thus, if these mRNAs failed to adequately translate, this
would have a detrimental impact on neuronal function given
that they are critically involved in supportive pathways like
metabolism and synapse regulation. Further, not only could
mRNAs become sequestered via their RNA-binding proteins,
but key astrocytic proteins are also sequestered, impeding
function. TDP-43 is a binding partner for EAAT2, the
glutamate transporter introduced above, and it has been
shown that TDP-43 aggregation correlates with decreased
EAAT1/2 glutamate transporter levels in the spinal cords of both
an ALS mouse model (Tong et al., 2013) and human patients
(Rothstein et al., 1995). FMRP is a known binding partner
of TDP-43; in patients with Fragile × syndrome (whereby
they have a repeat-expansion in the FMR1 gene and acquire
FMRP inclusions), profiling these inclusions demonstrated that
many astrocytic proteins have been associated with these FMR
inclusions, including vimentin, GFAP, and hnRNP A2/B1 [and,
interestingly, myelin basic protein (MBP; Iwahashi et al., 2005)]
Given FMRP is a known binding partner of TDP-43, these
protein associations are relevant to ALS.
Thus, the sequestration of key RNA-binding proteins in
astrocytes is likely to have a detrimental effect by impeding the
trafficking of mRNAs critical for cellular function to their site of
local translation.
RNA TRAFFICKING IN
OLIGODENDROCYTES
Oligodendrocytes have been underappreciated for their role
in the CNS with the focus to date limited to their role in
myelination. Recent research has uncovered their ability to
metabolically support neurons through the shuttling of lactate
(Fünfschilling et al., 2012; Saab et al., 2013, 2016), much like
astrocytes, highlighting a critical role for oligodendrocytes in
neuronal health, function and survival. Each oligodendrocyte has
the capacity to produce up to 50 myelin sheaths, each of which
can be up to 60 µm in length (Hughes et al., 2018), so their
support and metabolic supply (and demand) is extensive.
It has long been established that many mRNAs in
oligodendrocytes are translated locally at the myelin sheath
(Campagnoni et al., 1980; Colman et al., 1982) including MBP
(Kristensson et al., 1986; White et al., 2008), myelin-associated
oligodendrocytic basic protein (MOPB; Holz et al., 1996),
carbonic anhydrase II (CAII; Ghandour and Skoff, 1991), tau
(LoPresti et al., 1995) and amyloid precursor protein (APP;
Garcia-Ladona et al., 1997). This extends to the involvement of
many RNA-binding proteins including hnRNP A2/B1, hnRNP
A1, hnRNP E1, hnRNP H/F and hnRNP K, to name a few (White
et al., 2008; Laursen et al., 2011; Torvund-Jensen et al., 2014).
hnRNP A1 and hnRNP A2/B1 are involved in MBP mRNA
trafficking and both are also known binding partners of G4C2
repeats and TDP-43 (Highley et al., 2014). Of relevance, hnRNP
A1 is also critically involved in the exon skipping of survival
motor neuron 2 (SMN2; Kashima et al., 2007), involved in
spinal muscular atrophy (SMA), another form of motor neuron
disease and hnRNP A2/B1 has been implicated in Alzheimer’s
disease (Mizukami et al., 2005). hnRNP A2/B1 and hnRNP A1, as
well as TDP-43, have intrinsically disordered, aggregation-prone
domains at their C-terminal end (Kim et al., 2013) supporting
the contention that these proteins are prone to fibrillization
and misfolding. Further, TDP-43 depletion leads to upregulation
of specific isoforms of hnRNP A1, one of which has been
reported to be highly prone to aggregation (Deshaies et al., 2018).
Another RNA-binding protein involved in MBP trafficking is
QKI; QKI mutant mice actually have impaired nuclear export
of MBP mRNA resulting in impaired myelination in these mice
(Larocque et al., 2002). QKI was characterized to interact with
hnRNP F and H during alternative splicing in myelinating glia
(Mandler et al., 2014). Further, post-mortem samples from ALS
patients harboring C9orf72 mutations demonstrated that RNA
foci sequester hnRNP H/F (Cooper-Knock et al., 2014); hnRNP
H/F is necessary for PLP/DM20 alternative splicing (Wang
et al., 2007, 2008), a process critical for normal myelination.
Of relevance, in human post-mortem tissue, it has been shown
that ALS patients have a significant reduction in MBP in both
the motor cortex and ventral spinal cord (Kang et al., 2013);
however, it remains unclear as to whether the reduced myelin
is a downstream effect of axonal loss or whether it is an intrinsic
deficit in oligodendrocytes.
Oligodendrocytes have a very low annual turnover of just 1 in
300 oligodendrocytes in humans, making them a very stable cell
type in the CNS (Yeung et al., 2014). The production of myelin,
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on the other hand, is a more dynamic process (Yeung et al., 2014)
with one cell possessing the ability to produce three times its
own weight in myelin per day, eventually supporting 100 times
its own cell weight in myelin (McLaurin and Yong, 1995;
Connor and Menzies, 1996; Ludwin, 1997). Thus, given that
an oligodendrocyte also has to metabolically support neurons
in addition to their own metabolically demanding myelination
requirements, this makes them vulnerable to processes that
may interfere with myelin modulation. Given that many of the
RNA-binding proteins that are critical for myelin-related mRNA
trafficking in oligodendrocytes have been implicated in ALS
pathology, this poses a risk to cellular function and their ability
to support neurons.
CONCLUSION
It is well established that the hallmark pathological signature
of ALS is misfolding and accumulation of aggregation-prone
proteins, the most common of these proteinopathies being
TDP-43. To date, very little attention has been given to the
role of glia, specifically astrocytes and oligodendrocytes, in the
pathogenesis of ALS as a result of intrinsic cellular deficits
arising from protein aggregation. It is known in neurons that
pathological protein aggregation, as well as the formation of RNA
foci in C9orf72 cases, can have a toxic gain-of-function effect by
sequestering other mRNAs and proteins, compromising normal
cellular function. We suggest this process is also occurring in
glia and is complicated by the fact that many critical mRNAs
required for normal astrocytic and oligodendroglial function are
locally translated. Given the association of many RNA-binding
proteins with the typical protein aggregations found in ALS cases,
and the known associations of these RNA-binding proteins with
key mRNAs in astrocytes and oligodendrocytes, we suggest that
this is a potential pathogenic pathway of disease contributing to
cellular dysfunction in patients with ALS.
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